Description: Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Home Page: palatin.com
0KF3 Technical Analysis
Cedar Brook Corporate Center
Cranbury,
NJ
08512
United States
Phone:
609 495 2200
Officers
| Name | Title |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, CEO & Director |
| Mr. Stephen T. Wills CPA, MST | CFO, COO, Executive VP, Treasurer & Secretary |
| Burns McClellan | Vice President of Investor Relations |
| Mr. Stephen A. Slusher Esq. | Chief Legal Officer |
| Dr. Michael B. Raizman M.D. | Chief Medical Officer |
| Mr. James E. Hattersley | Senior Vice President of Business Development |
| Mr. John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Mr. Robert Jordan | Senior Vice President of Program Operations |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 53.1622 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 30 |